Live
FierceBiotechMirum maps FDA path after anti-itch candidate scores ph. 2 winNovartisAfter March cuts, Novartis trims another 60 roles at US headquarters - Fierce PharmaFierceBiotechTakeda pivotal trial win improves convenience for PID patients relative to HyQviaBioWorldBiggest gainers and losers for April 27-May 1, 2026Endpoints NewsCelcuity breast cancer win; Odyssey plans $205M IPO; Latus Bio extends Series AFierceBiotechWindward catches $165M breeze to fuel long-acting TSLP ambitionsEndpoints NewsBiotech has a new startup model: Small team, big check and Chinese assetsThermo FisherThermo Fisher Scientific Introduces Gibco CTS DynaXS Single Use Bioreactor - Contract PharmaPfizerPfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era - Yahoo FinanceSiemens HealthineersCDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results - The Manila TimesSiemens HealthineersSiemens Healthineers testosterone assay maintains CDC certification By Investing.com - Investing.com CanadaPharmaVoiceProtein degraders gain speed as Arvinas scores landmark approval
Cell Jan 22, 2026

Identification of Or5v1/Olfr110 as an oxylipin receptor and anti-obesity target

Identification of Or5v1/Olfr110 as an oxylipin receptor and anti-obesity target

Original
Body unavailable. Use the original source.